Product logins

Find logins to all Clarivate products below.


Chronic Heart Failure – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF and the diagnosed prevalence of CHF for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s HF forecast answers the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with severe disease?
  • Of all AHF hospitalization events, how many in each of the major mature pharmaceutical markets are drug-treated?
  • Of all people diagnosed with CHF, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of HF over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HF subpopulations:

  • Diagnosed AHF events by ejection fraction.
  • Diagnosed AHF events by treatment status.
  • Diagnosed AHF events by subpopulation.
  • Diagnosed CHF prevalent cases by severity.
  • Diagnosed CHF prevalent cases by treatment scheme.
  • Diagnosed CHF prevalent cases by ejection fraction.
  • Diagnosed CHF prevalent cases by comorbidity.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…